Lexington Biosciences Inc (LXGTF)
OTHER OTC:LXGTF
US Market
Holding LXGTF?
Track your performance easily

Lexington Biosciences (LXGTF) Income Statement

8 Followers

Lexington Biosciences Income Statement

Last quarter (Q ), Lexington Biosciences's total revenue was C$―, a decrease of ― from the same quarter last year. In Q, Lexington Biosciences's net income was C$-65.60K. See Lexington Biosciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
C$ 189.34KC$ 175.97KC$ 324.24KC$ 480.62KC$ 533.53KC$ 2.34M
Operating Income
C$ -189.34KC$ -175.97KC$ -324.24KC$ -480.62KC$ -533.53KC$ -2.34M
Net Non Operating Interest Income Expense
----C$ 120.79K-
Other Income Expense
----C$ -615.47K-
Pretax Income
C$ -189.34KC$ -175.97KC$ -324.24KC$ -480.62KC$ -1.27MC$ -2.34M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
C$ -189.34KC$ -175.97KC$ -324.24KC$ -480.62KC$ -1.27MC$ -2.34M
Basic EPS
-C$ 0.01C$ 0.01C$ 0.04C$ -0.34C$ -6.20
Diluted EPS
-C$ 0.01C$ 0.01C$ 0.04C$ -0.34C$ -6.20
Basic Average Shares
C$ 109.83MC$ 27.46MC$ 27.46MC$ 12.05MC$ 3.79MC$ 379.46K
Diluted Average Shares
C$ 109.83MC$ 27.46MC$ 27.46MC$ 12.05MC$ 3.79MC$ 379.46K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
C$ 189.34KC$ 175.97K--C$ -533.53KC$ -2.34M
Net Income From Continuing And Discontinued Operation
C$ -189.34KC$ -175.97KC$ -324.24KC$ -480.62KC$ -1.27MC$ -2.34M
Normalized Income
C$ -139.16KC$ -129.34KC$ -238.32KC$ -353.25KC$ -317.82KC$ -1.72M
Interest Expense
------
EBIT
C$ -189.34KC$ -175.97KC$ -324.24KC$ -480.62KC$ -1.15MC$ -2.34M
EBITDA
C$ -189.34KC$ -175.97KC$ -324.24KC$ -480.62KC$ -1.15MC$ -2.34M
Currency in CAD

Lexington Biosciences Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis